Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2023-12-15FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
FDA approved a supplemental application for ZUBSOLV, resulting in updated labeling for buprenorphine/naloxone.
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride …
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for buprenorphine from Actavis Pharma, Inc. The action indicates an additional approval under an…
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for a buprenorphine and naloxone product by Lannett Company, Inc., resulting in approval of this gen…
-
FDA approval · 2023-12-15FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
FDA approves a supplemental application for SUBLOCADE (buprenorphine) by Indivior Inc., expanding the approved use of the extended-release i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for the generic fixed-dose combination of buprenorphine hydrochloride and naloxone hydrochloride dih…
-
FDA approval · 2023-12-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals, Inc)
FDA approved a supplemental application for methadone hydrochloride from Camber Pharmaceuticals, Inc. This action grants continued approval …
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for a generic buprenorphine and naloxone product from Rhodes Pharmaceuticals L.P., indicating regula…
-
FDA approval · 2023-12-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for methadone hydrochloride manufactured by Hikma Pharmaceuticals USA Inc., updating the approved pr…
-
FDA approval · 2023-12-15FDA Approved: BRIXADI — Supplemental Application (Braeburn Inc.)
The FDA approved Braeburn Inc.'s supplemental application for BRIXADI (buprenorphine), indicating an update to the product's labeling under …
-
FDA approval · 2023-12-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride by VistaPharm, LLC, indicating changes to the existing approval for the …
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal's supplemental application for a generic buprenorphine HCl and naloxone HCl product for opioid use disorder. This is an …
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Buprenorphine and Naloxone from Actavis Pharma, Inc.
-
FDA approval · 2023-12-15FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride (methadone) by VistaPharm, LLC. This represents an additional approval f…
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for buprenorphine by Sun Pharmaceutical Industries, Inc. This action approves changes to the bupreno…
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
The FDA approved a supplemental application for buprenorphine and naloxone (generic product) from PAI Holdings/PAI Pharma.
-
FDA approval · 2023-12-15FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
FDA approved a supplemental application for Accord Healthcare's generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate pro…
-
CLINICAL_TRIALS trial_result · 2023-12-12Clinical Trial Update: Opioid Treatment and Recovery Through a Safe Pain Management Program [NA]
ClinicalTrials.gov update shows the study 'Opioid Treatment and Recovery Through a Safe Pain Management Program' has completed and posted re…
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: Start Treatment and Recovery for Opioid Use Disorder [NA]
Completed clinical trial investigating initiation of treatment and recovery for opioid use disorder; results posted in 2023.
-
FDA approval · 2023-12-04FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for Methadone Hydrochloride by Ascend Laboratories, LLC under an ANDA. This action supplements t…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Opioid Modulation and Neural Reward Activation in Healthy Adults [Phase 1, Phase 2]
A Phase 1/2 clinical trial examining opioid modulation and neural reward activation in healthy adults, with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: A Safety Study of AZD4041 in Healthy Participants [Phase 1]
A Phase 1 safety study of AZD4041 in healthy participants has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Harnessing Digital Health to Understand Clinical Trajectories of Opioid Use Disorder
A completed clinical trial evaluating digital health methods to understand clinical trajectories in opioid-use disorder, with results posted…
-
CLINICAL_TRIALS trial_result · 2023-10-05Clinical Trial Update: Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder [Phase 2]
Phase 2 clinical trial evaluating cannabidiol's effects on reward- and stress-related neurocognitive processes in individuals with opioid us…
-
CLINICAL_TRIALS trial_result · 2023-10-03Clinical Trial Update: Opioid Prescription After Cesarean Trial [Phase 3]
A Phase 3 clinical trial evaluating opioid prescribing after cesarean delivery has completed, with results posted in 2023.